ROTTERDAM, Netherlands, Sept. 1, 2022
Research, Optical Interventions, and Education Initiatives Reflect Company’s Myopia Control & Management Leadership
ROTTERDAM, Netherlands , Sept. one, 2022 /PRNewswire/ — CooperVision’s global leadership in myopia control and management will be spotlighted next week at the 18 th annual International Myopia Conference , taking place in Rotterdam, the Holland . The meeting is expected to attract a record number of attendees, reflecting escalating interest inside understanding and addressing the disease and its bearing on children’s short- and long-term vision plus ocular health.
Among the highlights is a CooperVision symposium that will offer new insights into the treatment efficacy of the fastest growing eyes fit with MiSight® 1 day contact lenses * , derived from the particular world’s longest-running soft contact lens study among children. The particular international seven-year MiSight® one day clinical trial has become the gold standard for evaluating myopia control effectiveness because of its robust design, multi-country enrollment, and extent associated with professionally published and peer-reviewed data. The findings will be presented by Paul Chamberlain, BSc (Hons), CooperVision Senior Director of Research Programs, and Arthur Bradley , PhD, CooperVision Research Fellow, on Monday, September 5 , in 12: 30 pm CEST .
Additional new research findings that span the company’s comprehensive range of optical interventions—including MiSight® 1 day soft contact lenses, its ortho-k portfolio , and SightGlass Vision’s spectacle lenses incorporating Diffusion Optics Technology ™† , as well as related fitting tools—will be shared during multiple scientific papers and poster sessions.
“No one will be doing more than CooperVision to advance the science and practice of myopia control plus management. We are investing in every aspect of the category—elevating research and development, commercializing a broad product portfolio, educating eye care professionals (ECPs) and public officials, and raising awareness amongst parents, ” said Chamberlain. “Our extensive commitment is already making a difference, with tens of thousands of ECPs and children benefitting from our trustworthy scientific findings, comprehensive evidence-based interventions, plus knowledge sharing. It’s the privilege to help expand these impacts and encourage action during IMC 2022. ”
IMC’s Rotterdam location also provides an unique opportunity for participants to experience CooperVision’s BeNeLux approach , where the company is currently offering all three types of myopia control optical interventions in order to ECPs. Company representatives upon the CooperVision stand will certainly share best practices from this learning laboratory, which will turn out to be even more relevant as worldwide availability with regard to clinically useful interventions continues to grow.
For additional information on the particular 2022 IMC, visit www.internationalmyopiaconference.org .
2. U. S. Indications for Use: MiSight® one day (omafilcon A) soft (hydrophilic) contact lens for daily wear are indicated regarding the correction of myopic ametropia and for slowing the progression associated with myopia in children along with non-diseased eyes, who at the initiation of treatment are usually 8-12 years of age and have a refraction of -0. 75 to -4. 00 diopters (spherical equivalent) with ≤ 0. 75 diopters of astigmatism. The lens is to be discarded after each removal.
† This product is not approved in all markets.
CooperVision, a division of CooperCompanies (
NYSE: COO , Financial ), is one of the world’s leading manufacturers associated with contact lenses. The company produces a full array of every day disposable, two-week and monthly soft disposable lenses that feature advanced materials and optics, and premium rigid gas permeable lens for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; plus offers the most complete profile of spherical, toric and multifocal products available. Through a combination of innovative items and focused practitioner support, the company brings the refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com .
CooperCompanies (“Cooper”) is usually a global medical device company publicly traded on the particular NYSE (
NYSE: COO , Financial ). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products intended for lens users and providing focused practitioner support. CooperSurgical is committed to advancing the wellness of women, babies plus families with its diversified portfolio of products and services focusing upon medical devices and fertility & genomics. Headquartered within San Ramon, Calif. , Cooper has a workforce of a lot more than 12, 000 along with products sold in over 100 countries. To find out more, please check out www.coopercos.com .
Mike McDougall , APR, Fellow PRSA, McDougall Communications
[email protected] or +1-585-434-2150
View original content to download multimedia: https://www.prnewswire.com/news-releases/coopervision-to-share-new-analysis-of-misight-1-day-treatment-effects-during-international-myopia-conference-event-301615771.html